Last update 16 May 2024

Avacincaptad pegol

Overview

Basic Info

Drug Type
Aptamers
Synonyms
Anti-C5 aptamer, Avacincaptad pegol sodium (USAN), Zimura
+ [3]
Target
Mechanism
C5 inhibitors(Complement C5 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (04 Aug 2023),
RegulationBreakthrough Therapy (US), Priority Review (US)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D11748--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Geographic Atrophy
US
04 Aug 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Geographic AtrophyNDA/BLA
EU
17 Aug 2023
Age Related Macular DegenerationPhase 3
AR
22 Jun 2020
dry age-related macular degenerationPhase 3
LV
20 Jan 2016
dry age-related macular degenerationPhase 3
CZ
20 Jan 2016
Dystrophy, MacularPhase 3--
dry age-related macular degenerationPhase 2
IL
20 Jan 2016
dry age-related macular degenerationPhase 2
HR
20 Jan 2016
dry age-related macular degenerationPhase 2
HU
20 Jan 2016
dry age-related macular degenerationPhase 2
US
20 Jan 2016
dry age-related macular degenerationPhase 2
EE
20 Jan 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
447
kfstskhjri(oxuxagxvqd) = fmzsoadrqv odjjjdjosa (wgwprtzipz )
Positive
06 Sep 2022
Sham
kfstskhjri(oxuxagxvqd) = cvcdqfiuge odjjjdjosa (wgwprtzipz )
Phase 2/3
286
septqhzucs(mbqvfzzzfj) = There were no avacincaptad pegol-related adverse events (AEs) or inflammation cpyhhyimkf (yqykgyjgdr )
-
01 Sep 2020
Phase 1
Wet age-related macular degeneration
complement-associated SNP
58
(rmwwtlzash) = fxozueffpq xuylflyxed (ywqixvyxld )
Positive
01 Apr 2010
Phase 2/3
-
Avacincaptad pegol 2 mg
yxieqcwdeh(cyoochpyja) = tkxjcosqnd fiuvqoywbm (lldqtigvip )
-
01 May 2022
avacincaptad pegol
yxieqcwdeh(cyoochpyja) = cbdrtvuykm fiuvqoywbm (lldqtigvip )
Not Applicable
4,052
Intravitreal lampalizumab
(uyuuekrzjp) = Progression to MNV or exudative AMD is a possible emergent adverse event of complement inhibition, requiring careful consideration should these agents be used clinically jjuhhlqadv (yyxcjihpbg )
-
14 Jun 2023
Intravitreal pegcetacoplan
Not Applicable
-
286
(jxgbreewug) = rnxaecoenk pbhimsmvio (ijgezgqasx )
-
13 Nov 2021
Avacincaptad Pegol 4mg
(jxgbreewug) = smwtlofjac pbhimsmvio (ijgezgqasx )
Phase 3
-
(dnwdvpsrbo) = IZERVAY was well tolerated over 2 years, with one case each of non-serious intraocular inflammation (IOI) and culture-positive endophthalmitis. There were no cases of ischemic neuropathy or retinal vasculitis. fxvhddblwr (nghbyrhulm )
Positive
04 Nov 2023
Phase 2/3
Ellipsoid Zone (EZ) At-Risk
194
fezknufniz(zcbnzebfgu) = mpilswwgjx zpaavpvzgu (fyvyjyfmpb )
-
23 Apr 2023
Sham
fezknufniz(zcbnzebfgu) = lcmtwdnwrj zpaavpvzgu (fyvyjyfmpb )
Not Applicable
-
Avacincaptad pegol 2 mg
(ydaboqxpgw) = There were no significant differences in best-corrected visual acuity or low-luminance visual acuity between avacincaptad and sham-treated patients fqrimasrep (bmquilsrel )
Positive
01 Jun 2021
Phase 2/3
624
(GATHER1)
orzsasjjno(zrwxddopaf) = qsfqadgbns hmlwqdjimy (iowdplibxj )
Positive
04 Aug 2023
Sham
(GATHER1)
orzsasjjno(zrwxddopaf) = jendtjvsin hmlwqdjimy (iowdplibxj )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free